Price history
¥1,938Latest+142.9%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview
Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
News
Key numbersShowing 8 of 17
PBR
17.73How many times the company's net assets? Around 1x is generally considered a benchmark.ROE
-1.0%Earning power. A figure above 10% is generally considered good.Dividend yield
0.0%The annual dividend as a percentage of the share price.Market capitalization
¥87bnShare price × number of shares. The value of the entire company.Equity ratio
81.5%The proportion of assets funded by money that does not have to be repaid.Operating margin
-10.3%The percentage of revenue remaining from the company’s core business.Revenue growth (3 years)
19.6%The average annual growth in sales over the past three years.Forward P/E
197.31Forward P/E based on estimated earnings for the next fiscal year.What to watch next
Ramp-up following completion of the MBE equipment relocation and disclosure of progress on the plan to quadruple production capacity in fiscal 2027
FY2027, based on the current planImpact HighLikelihood Medium
Concrete progress toward order intake and the transition to mass production for Lantana, the all-in-one compact visible laser, including its contribution to sales, yield and gross margin
From November 2025 onward, with continued monitoring in the latest quarterImpact MediumLikelihood Medium
Results of test marketing for RETISSA VIEWCLEAR, including signs of product-market fit and distribution expansion
Starts in May 2026, with results to followImpact MediumLikelihood Low
Medical business: resumption of NEO sales following the MEOCHECK voluntary recall and stabilization of regulatory and quality matters, reducing the risk of recurrence
2026, following the relaunch under the NEO nameImpact HighLikelihood Medium
Development progress from business cooperation with TDK, including the transfer of patent rights and optical units and modules related to retinal projection
From the signing of the agreement in June 2026, depending on development milestonesImpact MediumLikelihood Low
What to watch next
Who owns itTop holders total 7.8%
Listed holders 7.8%Everyone else 92.2%
JPMorgan Chase Bank, N.A., etc. (standing proxy: MUFG Bank, Ltd.)1.31%
Morgan Stanley MUFG Securities Co., Ltd.0.98%
Ishii Yoshiaki (石井 良明)0.94%
BNY GCM CLIENT ACCOUNT JPRD AC ISG (FE-AC)0.91%
SBI SECURITIES CO., LTD.0.74%
Société Générale EQ CO0.61%
Kawamoto Toshie (川本 敏江)0.60%
Nomura Securities Co., Ltd.0.59%
2 other listed holders1.08%
| Holder | Ownership (%) |
|---|---|
| JPMorgan Chase Bank, N.A., etc. (standing proxy: MUFG Bank, Ltd.) | 1.31 |
| Morgan Stanley MUFG Securities Co., Ltd. | 0.98 |
| Ishii Yoshiaki (石井 良明) | 0.94 |
| BNY GCM CLIENT ACCOUNT JPRD AC ISG (FE-AC) | 0.91 |
| SBI SECURITIES CO., LTD. | 0.74 |
| Société Générale EQ CO | 0.61 |
| Kawamoto Toshie (川本 敏江) | 0.60 |
| Nomura Securities Co., Ltd. | 0.59 |
| 2 other listed holders | 1.08 |
This company's documents
Filings
Timely disclosures
- 2026-09-24(Amendment) Partial amendment to the "Notice Concerning the Recording of Extraordinary Loss"
- 2026-09-11Notice Regarding the Recognition of Extraordinary Loss
- 2026-09-08Notice Regarding the Resumption of Production Operations for Crystal Growth Equipment (MBE Equipment)
- 2026-08-10Notice Regarding the Recognition of Extraordinary Loss
- 2026-08-10Earnings Presentation Materials for the First Quarter of the Fiscal Year Ending March 2027
- 2026-08-10Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 2027 [Japanese GAAP] (Non-consolidated)
- 2026-08-07Notice of Completion of the Allocation of New Shares as Restricted Stock-Based Compensation
- 2026-07-09Notice Regarding the Issuance of New Shares as Restricted Stock Compensation
21 more
- 2026-07-03Notice Regarding the Release of the Transcript of the 20th Annual General Meeting of Shareholders
- 2026-06-24Corporate Governance Report 2026/06/24
- 2026-06-24Executive structure
- 2026-06-24Presentation Materials on Business Plans and Growth Potential
- 2026-06-02Notice of Convocation of the 2026 Annual General Meeting of Shareholders and Meeting Materials
- 2026-06-01Notice Regarding Revisions to the Full-Year Earnings Forecast for the Fiscal Year Ending March 2027
- 2026-06-01Notice Regarding Business Collaboration with TDK Corporation on an Optical Engine for XR Glasses Using Retinal Projection Technology and the Recognition of an Extraordinary Gain
- 2026-05-22Notice of Publication of the Transcript of the Financial Results Briefing for Institutional Investors for the Fiscal Year Ending March 2026
- 2026-05-21Notice of Transcript Release: IR Seminar for Individual Investors
- 2026-05-14Notice Regarding the Selection of Candidates for Directors (Excluding Directors Who Are Audit and Supervisory Committee Members)
- 2026-05-14Notice Regarding the Introduction of a Pre-Delivery Restricted Stock Compensation Plan for Executive Directors
- 2026-05-14Notice Concerning the Reduction of Stated Capital and Capital Reserves and the Appropriation of Surplus
- 2026-05-14Notice Regarding the Recognition of Extraordinary Loss
- 2026-05-14Earnings Presentation Materials for the Fiscal Year Ending March 2026
- 2026-05-14Financial Results for the Fiscal Year Ending March 2026 [Japanese GAAP] (Non-consolidated)
- 2026-05-14Notice of the Start of Test Marketing for the RETISSA VIEWCLEAR Smartphone-Compatible Retinal Projection Accessory
- 2026-05-11Articles of Incorporation 2026/04/15
- 2026-04-30Notice Regarding Revisions to Full-Year Earnings Forecasts for the Fiscal Year Ending March 2026
- 2026-03-12Notice Regarding the Decision on the Date of Head Office Relocation
- 2026-03-12Notice Regarding Borrowing of Funds
- 2026-03-11量子ドット・コムレーザに関する共同研究開発に向けた基本合意書締結のお知らせ
Threads
- 2026-09-19Risks of Relocating the Laser Device Site and Starting Up MBE Equipment
- 2026-08-10Assumption of Losses Associated with Launching the Laser Eyewear Business
- 2026-08-10Expanding quantum-dot lasers into silicon photonics and LiDAR
- 2026-08-1020% annual growth in certified customers and 25% annual growth in the laser device business
- 2026-08-10Losses and delayed profitability due to continued R&D investment
- 2026-08-10Laser device business turns profitable in the first half
- 2026-08-10Expansion of Measurement Facilities and Enhancement of Manufacturing Equipment for the Laser Device Business
- 2026-08-10Development of enabling technologies and monetization of intellectual property to realize smart glasses
66 more
- 2026-08-10Medium-term management plan targeting company-wide profitability in the fiscal year ending March 2027
- 2026-08-10Monetization of visual information devices through joint commercialization with other companies and technology licensing
- 2026-08-10B2B optical-module business using semiconductor laser and retinal-projection technologies
- 2026-08-07Introduction of a restricted stock compensation plan
- 2026-06-24Launch and sales expansion of the laser eyewear business
- 2026-06-24Growing demand for R&D and working capital and financing risk
- 2026-06-24Strengthening Corporate Governance
- 2026-06-24Transition to a Company with an Audit and Supervisory Committee and Oversight by Outside Directors
- 2026-06-24Establishing Internal Control and Risk Management Systems
- 2026-06-24Achieving sales of more than ¥10 billion under “10 by 10 to 100”
- 2026-06-19Sourcing components and manufacturing laser eyewear for sale
- 2026-06-19Order trends by application in the laser device business
- 2026-06-19Continued product development and R&D
- 2026-06-19Allocation of public offering proceeds to laser eyewear manufacturing costs
- 2026-06-19Cumulative laser eyewear sales target of 100,000 units and annual production target of 50,000 units
- 2026-06-19Setting a numerical target for gross profit margin
- 2026-06-19Development and commercialization of optometry equipment using retinal-scanning technology
- 2026-06-19Strengthening the marketing and sales structure and new product development capabilities
- 2026-06-19Deteriorating economic conditions and capital spending appetite
- 2026-06-19Unstable supply, price fluctuations and quality deterioration of components and materials
- 2026-06-19Overseas sales and changes in the international environment
- 2026-06-19Constraints arising from a small organization and its internal management structure
- 2026-06-19Dilution of share value from the exercise of stock options
- 2026-06-19Metrics and targets for optimizing human capital
- 2026-06-19Review of Sales Plan for Laser Eyewear Products and Loss on Inventory Valuation
- 2026-06-19Approval and use of the SME Growth Acceleration Subsidy
- 2026-06-02Streamlining the capital structure through a capital reduction without consideration and appropriation of surplus
- 2026-05-14Withdrawal of medical-device approval due to efficacy or safety issues
- 2026-05-14Regulatory compliance issue involving MEOCHECK results and voluntary recall
- 2026-05-14Voluntary recall and software remediation to bring MEOCHECK into regulatory compliance
- 2025-11-13Commitment Lines and Financial Covenants
- 2025-11-13Status of Non-Payment of Dividends
- 2025-11-13Supplying high-quality, stable products
- 2025-11-13Unexpected foreign-exchange fluctuations
- 2025-11-13Dependence on the Representative Director and President
- 2025-11-13Change of Audit Firm
- 2025-11-13Changes in the Estimate of Asset Retirement Obligations
- 2025-06-20Corporate slogan: “Illuminate Human Potential.”
- 2025-06-20Fabless manufacturing and horizontal division of labor
- 2025-06-20Development and volume production of lasers across a broad wavelength range
- 2025-06-20Medical-device and overseas expansion of retinal-scanning laser eyewear
- 2025-06-20Maintaining and developing collaboration with horizontal-division partners
- 2025-06-20Strengthening internal management and IR structures and developing human resources
- 2025-06-20Lower orders due to changes in contractors’ business conditions or policies
- 2025-06-20Sales agents’ and partners’ failure to meet targets or changes in their policies
- 2025-06-20Intellectual property infringement and legal disputes
- 2025-06-20Allocation of proceeds from stock acquisition rights with exercise-price adjustment provisions to production-capacity expansion and M&A
- 2025-06-20Solving Social Issues through the Business and Achieving Sustainable Growth
- 2025-06-20Targets for increasing the number of companies adopting the eye health check service and the number of people receiving checks
- 2024-06-28Dependence on Corporate Customers for the Eye Health Check Service
- 2024-06-28Damages claims and litigation arising from product defects and other problems
- 2024-02-14Weak demand and deteriorating profitability caused by COVID-19
- 2023-08-10Financing Through Stock Acquisition Rights with a Variable Exercise Price
- 2023-02-14Balancing infection control and productivity through telework and other measures
- 2023-02-14Transfer of retinal-scanning product development to the laser eyewear business
- 2022-06-28Tokyo Stock Exchange Mothers listing and financing through a public offering
- 2022-06-28Market contraction caused by laser substitutes and low-cost mass-produced products
- 2022-06-28Financial deterioration or quality incidents at contract manufacturers
- 2022-06-28Product defects and quality problems
- 2022-06-28Risk of being unable to provide new products and technologies supported by the market
- 2022-06-28Leakage of technical and sales information, cyberattacks and system disruptions
- 2022-06-28Difficulty securing personnel and rising labor costs
- 2022-06-28Loss of technology and know-how through employee departures
- 2022-06-28Natural disasters such as earthquakes
- 2022-06-28Adoption of Accounting Standards for Revenue Recognition and Fair Value Measurement
- 2022-06-28International standardization of image-quality assessment methods for scanning retinal projection devices